JP2001503258A - 遺伝子発現および搬送系および用途 - Google Patents
遺伝子発現および搬送系および用途Info
- Publication number
- JP2001503258A JP2001503258A JP51952098A JP51952098A JP2001503258A JP 2001503258 A JP2001503258 A JP 2001503258A JP 51952098 A JP51952098 A JP 51952098A JP 51952098 A JP51952098 A JP 51952098A JP 2001503258 A JP2001503258 A JP 2001503258A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- dna
- plasmid
- coding sequence
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 110
- 238000012384 transportation and delivery Methods 0.000 title abstract description 45
- 108020004414 DNA Proteins 0.000 claims abstract description 165
- 239000013612 plasmid Substances 0.000 claims abstract description 150
- 108091026890 Coding region Proteins 0.000 claims abstract description 91
- 150000002632 lipids Chemical class 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 58
- 241000124008 Mammalia Species 0.000 claims abstract description 21
- 108010065805 Interleukin-12 Proteins 0.000 claims description 132
- 102000013462 Interleukin-12 Human genes 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 97
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 238000013518 transcription Methods 0.000 claims description 35
- 230000035897 transcription Effects 0.000 claims description 34
- -1 cationic lipid Chemical class 0.000 claims description 30
- 230000007935 neutral effect Effects 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 125000002091 cationic group Chemical group 0.000 claims description 21
- 239000002502 liposome Substances 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 150000001720 carbohydrates Chemical class 0.000 claims description 11
- 208000006673 asthma Diseases 0.000 claims description 10
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000012646 vaccine adjuvant Substances 0.000 claims description 3
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 4
- 238000005507 spraying Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000001571 immunoadjuvant effect Effects 0.000 abstract 1
- 239000000568 immunological adjuvant Substances 0.000 abstract 1
- 229940117681 interleukin-12 Drugs 0.000 description 111
- 210000004027 cell Anatomy 0.000 description 75
- 238000009472 formulation Methods 0.000 description 47
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 46
- 108090000663 Annexin A1 Proteins 0.000 description 45
- 210000004072 lung Anatomy 0.000 description 42
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 38
- 239000000443 aerosol Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- 239000013598 vector Substances 0.000 description 23
- 108020005067 RNA Splice Sites Proteins 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 108020003589 5' Untranslated Regions Proteins 0.000 description 19
- 108010058846 Ovalbumin Proteins 0.000 description 19
- 229940092253 ovalbumin Drugs 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 108700010070 Codon Usage Proteins 0.000 description 18
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000032258 transport Effects 0.000 description 16
- 238000001415 gene therapy Methods 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 108091092195 Intron Proteins 0.000 description 13
- 238000002663 nebulization Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 108020005345 3' Untranslated Regions Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000000833 heterodimer Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000000889 atomisation Methods 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000001124 posttranscriptional effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 5
- 101001090483 Homo sapiens Glutathione S-transferase LANCL1 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 4
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 4
- 101000912009 Homo sapiens Cyclin-dependent kinase 5 activator 1 Proteins 0.000 description 4
- 101001038346 Homo sapiens GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 4
- 101000980900 Homo sapiens Sororin Proteins 0.000 description 4
- 101000808126 Homo sapiens Uroplakin-3b Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002716 delivery method Methods 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 3
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000004581 coalescence Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 102000048091 human CDCA5 Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 210000000633 nuclear envelope Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 2
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108091026828 U2 spliceosomal RNA Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- NWXMGUDVXFXRIG-NAOJVREFSA-N (4s,4as,5as,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2C(O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-NAOJVREFSA-N 0.000 description 1
- PNXSUXRNBHUCSF-HSYVXBRLSA-N 107658-43-5 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)OC(=O)CC[C@@H](C(=O)N[C@@H](C)C(=O)OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C1C=NC=N1 PNXSUXRNBHUCSF-HSYVXBRLSA-N 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 108010087294 GALA peptide Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100006310 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chol-1 gene Proteins 0.000 description 1
- 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000002338 electrophoretic light scattering Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 組換え真核生物遺伝子の発現のためのプラスミドであって、 第一の5’−非翻訳領域、第一の合成イントロン、第一のコード配列、および第 一の合成3’−非翻訳領域/ポリ(A)シグナルに転写的に連結した第一の転写 調節配列を含む第一の転写単位、ここで前記第一の合成イントロンは前記調節配 列と前記第一のコード配列との間にあり;および 第二の5’−非翻訳領域、第二の合成イントロン、第二のコード配列、および第 二の合成3’−非翻訳領域/ポリ(A)シグナルに転写的に連結した第二の転写 調節配列を含む第二の転写単位、ここで前記第二の合成イントロンは前記調節配 列と前記第二のコード配列との間にある、 を含むことを特徴とするプラスミド。 2. 前記第一の転写調節配列または前記第二の転写調節配列がサイトメガロウ イルスプロモーター/エンハンサー配列を含む、請求項1記載のプラスミド。 3. 前記第一のコード配列または前記第二のコード配列が治療用分子または治 療用分子のサブユニットをコードする、請求項1記載のプラスミド。 4. 前記第一の転写調節配列および第二の転写調節配列が同一である、請求項 1記載のプラスミド。 5. 前記第一の転写調節配列および第二の転写調節配列が異なる、請求項1記 載のプラスミド。 6. 前記第一のコード配列および前記第二のコード配列が、ヒトIL−12の p40サブユニットをコードする配列およびヒトIL−12のp35サブユニッ トをコードする配列を含む、請求項1記載のプラスミド。 7. ヒトIL−12のp40サブユニットをコードする前記配列がヒトIL− 12のp35サブユニットをコードする前記配列の5’側にある、請求項6記載 のプラスミド。 8. 組換え真核生物遺伝子の発現のためのプラスミドであって、可変スプライ シングを有するイントロン、第一のコード配列、および第二のコード配列を含む プラスミド。 9.さらに、 第一のコード配列および第二のコード配列に転写的に連結した転写調節配列; 5’−非翻訳領域; 前記第一のコード配列の5’側のイントロン; 前記第一のコード配列の3’側かつ前記第二のコード配列の5’側にある代替ス プライシング部位;および 3’−非翻訳領域/ポリ(A)シグナル を含む、請求項8記載のプラスミド。 10. 前記第一のコード配列または前記第二のコード配列が、治療用分子また は治療用分子のサブユニットをコードする、請求項9記載のプラスミド。 11. 前記転写調節配列がサイトメガロウイルスプロモーター/エンハンサー 配列を含む、請求項9記載のプラスミド。 12. 前記第一のコード配列および前記第二のコード配列が、ヒトIL−12 のp40サブユニットをコードする配列およびヒトIL−12のp35サブユニ ットをコードする配列を含む、請求項8記載のプラスミド。 13. 組換え真核生物遺伝子の発現のためのプラスミドであって、 第一のコード配列、IRES配列、第二のコード配列、および3’一非翻訳領域 /ポリ(A)シグナルに転写的に連結した転写調節配列、ここで前記IRES配 列は前記第一のコード配列と前記第二のコード配列との間にあり;および 前記プロモーターと前記第一のコード配列との間にあるイントロン を含むことを特徴とするプラスミド。 14. 前記転写調節配列がサイトメガロウイルスプロモーター/エンハンサー 配列を含む、請求項13記載のプラスミド。 15. 前記第一のコード配列および前記第二のコード配列が、ヒトIL−12 のp40サブユニットをコードする配列およびヒトIL−12のp35サブユニ ットをコードする配列を含む、請求項13記載のプラスミド。 16. 前記IRES配列が、脳心筋炎ウイルスからのものである、請求項13 記載のプラスミド。 17. 天然のヒトIL−12サブユニットコード配列に対して50%未満の同 一性を有する合成ヌクレオチド配列を含む、ヒトIL−12サブユニットをコー ドするDNA配列。 18. 前記合成ヌクレオチド配列が配列番号3の配列に対して少なくとも99 %の配列同一性を有する配列を含む、請求項17記載のDNA配列。 19. 前記合成ヌクレオチド配列が、配列番号3または4の配列と同一のヌク レオチド配列を含む、請求項18記載のDNA配列。 20. 前記合成ヌクレオチド配列が、配列番号7の配列に対して少なくとも9 9%の配列同一性を有する配列を含む、請求項17記載のDNA配列。 21. 前記合成ヌクレオチド配列が配列番号7または8の配列と同一のヌクレ オチド配列を含む、請求項20記載のDNA配列。 22. 哺乳動物においてDNA分子を搬送するための組成物であって、 約800ナノメーターの押し出し成形サイズを有するリポソームとして調製され た、中性捕脂質を有する陽イオン性脂質;および コード配列を含む若干量のDNA、 を含む組成物。 23. 前記DNAの少なくとも約80%がスーパーコイル型である、請求項2 2記載の組成物。 24. 前記DNAの少なくとも約90%がスーパーコイル型である、請求項2 3記載の組成物。 25. 前記DNAの少なくとも約95%がスーパーコイル型である、請求項2 4記載の組成物。 26. 前記陽イオン性脂質および前記DNAが負対正の電荷比が約1:3で存 在する、請求項22記載の組成物。 27. さらに等張炭水化物溶液を含む、請求項22記載の組成物。 28. 前記等張炭水化物溶液が約10%ラクトースから本質的になる、請求項 27記載の組成物。 29. 前記陽イオン性脂質がDOTMAであり、前記中性捕脂質がコレステロ ールである、請求項22記載の組成物。 30. 哺乳動物においてDNA分子を搬送するための組成物であって、 中性捕脂質を有する陽イオン性脂質;および コード配列を含む若干量のDNAを含み、 前記陽イオン性脂質および前記DNAが負対正の電荷比が約1:3で存在するこ とを特徴とする組成物。 31. 前記DNAの少なくとも約80%がスーパーコイル型である、請求項3 0記載の組成物。 32. 前記DNAの少なくとも約90%がスーパーコイル型である、請求項3 1記載の組成物。 33. 前記DNAの少なくとも約95%がスーパーコイル型である、請求項3 2記載の組成物。 34. さらに等張炭水化物溶液を含む、請求項30記載の組成物。 35. 前記等張炭水化物溶液が約10%ラクトースから本質的になる、請求項 34記載の組成物。 36. 前記陽イオン性脂質がDOTMAであり、前記中性捕脂質がコレステロ ールである、請求項30記載の組成物。 37. DNAを哺乳動物に搬送するための組成物を製造する方法であって、 a. コード配列を含むDNAを調製し; b. 約800nmの押し出し成形サイズを有するリポソームを調製し、ここで 前記リポソームは陽イオン性脂質および中性捕脂質を含み;そして c. 前記リポソームを、前記陽イオン性脂質および前記DNAが負対正の電荷 比が約1:3で存在するような量で前記DNAと組み合わせる、 の各工程を含む方法。 38. 哺乳動物の病状または疾患を治療する方法であって、 前記病状または疾患を患う哺乳動物に、哺乳動物中にDNA分子を搬送するため の組成物を投与することを含み、 前記DNAは治療用分子またはそのサブユニットをコードするコード配列を含み 、かつ 前記組成物は陽イオン性脂質、中性捕脂質および前記DNAを含み、前記陽イオ ン性脂質および前記DNAについて負対正の電荷比が約1:3である、 ことを特徴とする方法。 39. 前記組成物が超音波噴霧により投与されるために調製される、請求項3 8記載の方法。 40. 前記DNAが、ヒトIL−12p40サブユニットおよびp35サブユ ニットをコードする2つのコード配列を含む、請求項38記載の方法。 41. 前記疾患または病状が喘息である、請求項38記載の方法。 42. 前記疾患または病状が癌である、請求項38記載の方法。 43. 陽イオン性脂質、中性捕脂質、およびDNAを含むワクチンアジュバン トであって、 前記DNAはIL−12のp40サブユニットおよびIL−12のp35サブユ ニットをコードする配列を含み、かつ 前記陽イオン性脂質および前記DNAは、負対正の電荷比が約1:3で存在する ことを特徴とするワクチンアジュバント。 44. ワクチンに対する哺乳動物の応答を増強する方法であって、前記哺乳動 物にワクチンおよびアジュバントを投与することを含み、 前記アジュバントは陽イオン性脂質、中性捕脂質、およびDNAを含み、前記D NAはIL−12のp40サブユニットおよびIL−12のp35サブユニット をコードする配列を含み、かつ 前記陽イオン性脂質および前記DNAは、負対正の電荷比が約1:3で存在する 、ことを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2868796P | 1996-10-18 | 1996-10-18 | |
US60/028,687 | 1996-10-18 | ||
PCT/US1997/018832 WO1998017814A2 (en) | 1996-10-18 | 1997-10-10 | Gene expression and delivery systems and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001503258A true JP2001503258A (ja) | 2001-03-13 |
Family
ID=21844877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51952098A Ceased JP2001503258A (ja) | 1996-10-18 | 1997-10-10 | 遺伝子発現および搬送系および用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020119940A1 (ja) |
EP (1) | EP0931156A2 (ja) |
JP (1) | JP2001503258A (ja) |
AU (1) | AU4908197A (ja) |
CA (1) | CA2268276A1 (ja) |
WO (1) | WO1998017814A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007259775A (ja) * | 2006-03-29 | 2007-10-11 | National Institute Of Agrobiological Sciences | 効率的なトランスジェニックカイコの作出方法 |
JP2015501840A (ja) * | 2011-12-12 | 2015-01-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
JP2016514477A (ja) * | 2013-03-30 | 2016-05-23 | ウーシャ バイオテック リミテッド | 哺乳動物細胞内で生物活性タンパク質を発現させるための方法および構築物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
AU778988B2 (en) * | 1998-06-04 | 2004-12-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Nucleic acid vaccines for prevention of flavivirus infection |
US7504253B2 (en) * | 1999-06-11 | 2009-03-17 | The Burnham Institute For Medical Research | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
US7833754B2 (en) | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
US8715964B2 (en) | 2008-05-11 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Expression of IL-12 family heterodimers |
ES2941411T3 (es) | 2016-05-18 | 2023-05-22 | Modernatx Inc | Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos |
AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
WO2023023503A1 (en) * | 2021-08-16 | 2023-02-23 | Yale University | Interleukin-12 variants and methods of use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5208036A (en) * | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
CA2441636A1 (en) * | 1988-11-10 | 1990-05-10 | The Wistar Institute Of Anatomy And Biology | Natural killer stimulatory factor |
EP0790255B1 (en) * | 1989-12-22 | 2007-08-08 | F. Hoffmann-La Roche Ag | Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
DE4228457A1 (de) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
JPH09500013A (ja) * | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
IL114576A0 (en) * | 1994-07-22 | 1995-11-27 | Merck & Co Inc | Polynucleotide herpes virus vaccine |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
WO1997000321A1 (en) * | 1995-06-14 | 1997-01-03 | Commonwealth Scientific And Industrial Research Organisation | Immune response modulators and uses therefor |
JP2001502666A (ja) * | 1996-09-12 | 2001-02-27 | ジェネメディシン,インコーポレイテッド | 肺遺伝子送達のための組成物および方法 |
-
1997
- 1997-10-10 EP EP97911788A patent/EP0931156A2/en not_active Withdrawn
- 1997-10-10 AU AU49081/97A patent/AU4908197A/en not_active Abandoned
- 1997-10-10 JP JP51952098A patent/JP2001503258A/ja not_active Ceased
- 1997-10-10 WO PCT/US1997/018832 patent/WO1998017814A2/en not_active Application Discontinuation
- 1997-10-10 CA CA002268276A patent/CA2268276A1/en not_active Abandoned
-
2001
- 2001-01-03 US US09/754,014 patent/US20020119940A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007259775A (ja) * | 2006-03-29 | 2007-10-11 | National Institute Of Agrobiological Sciences | 効率的なトランスジェニックカイコの作出方法 |
JP2015501840A (ja) * | 2011-12-12 | 2015-01-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
JP2018134100A (ja) * | 2011-12-12 | 2018-08-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
JP2021042245A (ja) * | 2011-12-12 | 2021-03-18 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil−12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
JP7129106B2 (ja) | 2011-12-12 | 2022-09-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改善されたil-12遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
JP2016514477A (ja) * | 2013-03-30 | 2016-05-23 | ウーシャ バイオテック リミテッド | 哺乳動物細胞内で生物活性タンパク質を発現させるための方法および構築物 |
Also Published As
Publication number | Publication date |
---|---|
WO1998017814A3 (en) | 1998-08-27 |
US20020119940A1 (en) | 2002-08-29 |
CA2268276A1 (en) | 1998-04-30 |
WO1998017814A2 (en) | 1998-04-30 |
EP0931156A2 (en) | 1999-07-28 |
AU4908197A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2126103C (en) | Transfection of lung via aerosolized transgene delivery | |
JP3056782B2 (ja) | 標的器官内での遺伝子の発現用医薬組成物 | |
JP3710815B2 (ja) | Il−2発現に適したプラスミド | |
US6034072A (en) | IL-2 gene expression and delivery systems and uses | |
US7655772B2 (en) | Materials and methods for treatment of allergic diseases | |
WO2006076288A2 (en) | Dna constructs for long-term expression of intravascularly injected naked dna | |
JP2001523480A (ja) | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 | |
JP2000516472A (ja) | 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター | |
JP2001503258A (ja) | 遺伝子発現および搬送系および用途 | |
WO1998034952A9 (en) | Il-2 gene expression and delivery systems and uses | |
JP2002506647A (ja) | インターフェロンαプラスミドおよび送達システム、およびこれを作製しそして使用する方法 | |
AU726207B2 (en) | IL-12 gene expression and delivery systems and uses | |
Colledge | Cystic fibrosis gene therapy | |
KR20010114237A (ko) | 에어로졸 전달용 폴리에틸렌이민:dna 제형 | |
AU782051B2 (en) | Enhanced delivery via serpin enzyme complex receptor | |
EP1007549B1 (en) | Compositions and methods for highly efficient transfection | |
US20040047846A1 (en) | Ubiquitin promoter in vectors for gene therapy in respiratory tract | |
BROWN et al. | Propellant-driven aerosols of DNA plasmids for gene expression in the respiratory tract | |
US6479464B1 (en) | Compositions and methods for highly efficient transfection | |
AU2004237899A1 (en) | Gene expression and delivery systems and uses | |
Woll et al. | Gene therapy for lung cancer | |
US20020028193A1 (en) | Recombinant beta2-adrenergic receptor delivery and use in treating airway and vascular diseases | |
JP2003522133A (ja) | 持続性導入遺伝子発現を実現する方法 | |
CN117965584A (zh) | 一种编码IL-2融合蛋白的mRNA及其药物制剂与应用 | |
CN117377464A (zh) | 用于递送核酸的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070605 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070904 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080226 |